Trabectedin: An emerging therapeutic option in soft tissue sarcoma

European journal of Clinical and Medical Oncology

Volumn 2, Issue 1, 2010, Pages

  Blay, Jean Yves ^a,b,c,d,e  

^a CENTRE LÉON BÉRARD   (France)

^b INSERM   (France)

^c UNIVERSITÉ LYON 1   (France)

^d EORTC DATA CENTER   (Belgium)

^e Conticanet Network of Excellence ^*  (Belgium)

Author keywords

ET 743; Metastatic disease; Soft tissue sarcoma; Trabectedin

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CISPLATIN; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IRINOTECAN; MESNA; PAZOPANIB; SORAFENIB; TRABECTEDIN;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BONE MARROW SUPPRESSION; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEBRILE NEUTROPENIA; HEMORRHAGIC CYSTITIS; HEPATOBILIARY DISEASE; HUMAN; LEIOMYOSARCOMA; LEUKOPENIA; LIPOSARCOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; REVIEW; SEPSIS; SIDE EFFECT; SKIN TOXICITY; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

EID: 77956287630     PISSN: 17598958     EISSN: 17598966     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Schoffski P, Dumez H, Wolter P, Stefan C, Wozniak A, Jimeno J, et al. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. Expert Opin Pharmacother. 2008;9(9):1609-1618.
2. Ray Coquard I, Blay J-Y. Adult soft tissue sarcomas. Hospital Pharmacy Europe. 2008;37:19-23.
3. Cormier JN, Pollock RE. Soft tissue sarcomas. CA Cancer J Clin. 2004;54(2): 94-109.
4. Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med. 2005;353(7):701-711.
5. Practice guidelines in oncology: soft tissue sarcoma, version 3. US National Comprehensive Cancer Network. Available from: http://www.nccn.org/professionals/physician_gls/PDF/sarcoma. 2007.
6. Sleijfer S, Seynaeve C, Verweij J. Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist. 2005;10(10):833-841.
7. Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19 Suppl 2:ii89-93.
8. Tascilar M, Loos WJ, Seynaeve C, Verweij J, Sleijfer S. The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. Oncologist. 2007;12(11):1351-1360.
9. Carter NJ, Keam SJ. Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs. 2007;67(15):2257-2276.
10. Schoffski P, Wolter P, Clement P, Sciot R, De Wever I, Wozniak A, et al. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma. Future Oncol. 2007;3(4):381-392.
11. R; ET-743): a drug of marine origin for soft-tissue sarcoma. Hosp Pharm Eur. 2008;Mar-Apr:19-23.
12. Damia G, Silvestri S, Carrassa L, Filiberti L, Faircloth GT, Liberi G, et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer. 2001;92(4):583-588.
13. Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med. 2001;7(8):961-966.
14. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 2002;62(17):4899-4902.
15. Casado JA, Rio P, Marco E, Garcia-Hernandez V, Domingo A, Perez L, et al. Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin. Mol Cancer Ther. 2008;7(5):1309-1318.
16. Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004;22(8):1480-1490.
17. Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol. 2005;23(3):576-584.
18. Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol. 2004;22(5):890-899.
19. Babovic N, Jelic S, Milanovic N, Matkovic S. Pilot study of daily ifosfamide 1 g/m2 until grade III granulocytopenia as second-line chemotherapy for anthracycline-pretreated advanced soft tissue sarcoma. Tumori. 1998;84(6):677-680.
20. Le Cesne A, Antoine E, Spielmann M, Le Chevalier T, Brain E, Toussaint C, et al. High-dose ifosfamide: circumvention of resistance to standarddose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol. 1995;13(7): 1600-1608.
21. Bramwell VH, Mouridsen HT, Santoro A, Blackledge G, Somers R, Verwey J, et al. Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol. 1987;23(3):311-321.
22. van Oosterom AT, Mouridsen HT, Nielsen OS, Dombernowsky P, Krzemieniecki K, Judson I, et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer. 2002;38(18):2397-2406.
23. Toma S, Tucci A, Villani G, Carteni G, Spadini N, Palumbo R. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG). Anticancer Res. 2000;20(1B): 485-491.
24. Blackledge G, van Oosterom A, Mouridsen H, Steward WP, Buesa J, Thomas D, et al. Doxorubicin in relapsed soft tissue sarcoma: justification of phase II evaluation of new drugs in this disease. An EORTC Soft Tissue and Bone Sarcoma Group Study. Eur J Cancer. 1990; 26(2):139-141.
25. Verweij J, Lee SM, Ruka W, Buesa J, Coleman R, van Hoessel R, et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol. 2000;18(10):2081-2086.
26. Verweij J. Other endpoints in screening studies for soft tissue sarcomas. Oncologist. 2008;13 Suppl 2:27-31.
27. Schuetze SM, Baker LH, Benjamin RS, Canetta R. Selection of response criteria for clinical trials of sarcoma treatment. Oncologist. 2008;13 Suppl 2:32-40.
28. Van Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer. 2002;38(4):543-549.
29. Hollebecque A, Adenis A, Taieb S, Lebedinsky C, Penel N. Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients. Invest New Drugs. 2009.
30. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25(13):1753-1759.
31. Le Cesne A, Misset JL, Demetri G, Lopez-Martin JA, Blay JY, van Oosterom A, et al. Consistent evidence of activity of Ecteinascidin (ET-743) in pretreated, advanced Soft Tissue Sarcoma (STS): Results from a pooled analysis of three pivotal Phase II clinical trials (P2CT) and safety profile of a 24h. infusion schedule. Eur J Cancer. 2001;Suppl 6:Abstr 114.
32. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay J-Y, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;(in press).
33. Garcia-Carbonero R, Supko JG, Maki RG, Manola J, Ryan DP, Harmon D, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol. 2005;23(24):5484-5492.
34. Grosso F, Dileo P, Sanfilippo R, Stacchiotti S, Bertulli R, Piovesan C, et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer. 2006;42(10):1484-1490.
35. Grosso F, Jones RL, Blay JY, Judson IR, Le Cesne A, Poveda A, et al. Trabectedin (T) in Soft Tissue Sarcomas (STS) Carriying a Chromosomal Translocation: an Exploratory Analysis. 13th Annual Conective Tissue Oncology Society Meeting Proceedings Abstract 900; Seattle, WA; 2007.
36. Ruiz-Casado A, Lopez-Martin JA, Nieto A, Blay J-Y, Delaloge S, van Oosterom A, et al. Ecteinascidin in heavily pretreated advanced sarcoma patients as a compassionate basis. Proc Am Soc Clin Oncol 2002;21:Abstr 1631.
37. Mohan V, Chawla T, Alzwahereh K, Jeong W, Kita KY, Chua VS, et al. Updated results of Phase II study of trabectedin (ET-743) in pretreated patients with advanced/metastatic soft tissue sarcoma from a single institute. J Clin Oncol (Meeting Abstracts). 2008;26(15_suppl):21506.
38. Huygh G, Clement PM, Dumez H, Schoffski P, Wildiers H, Selleslach J, et al. Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients. Sarcoma. 2006;2006:56282.
39. Blay JY, von Mehren M, Samuels BL, Fanucchi MP, Ray-Coquard I, Buckley B, et al. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Clin Cancer Res. 2008; 14(20):6656-6662.
40. Keohan ML, Taub RN. Chemotherapy for advanced sarcoma: therapeutic decisions and modalities. Semin Oncol. 1997;24(5):572-579.
41. O'Byrne K, Steward WP. The role of chemotherapy in the treatment of adult soft tissue sarcomas. Oncology. 1999;56(1):13-23.
42. Connelly EF, Budd GT. Ifosfamide in the treatment of soft tissue sarcomas. Semin Oncol. 1996;23(3 Suppl 6):16-21.
43. Tursz T. High-dose ifosfamide in the treatment of advanced soft tissue sarcomas. Semin Oncol. 1996;23(3 Suppl 7):34-39.
44. Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies-dose-response and schedule dependence. J Clin Oncol. 1997;15(6):2378-2384.
45. Le Cesne A, Judson I, Crowther D, Rodenhuis S, Keizer HJ, Van Hoesel Q, et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 2000;18(14):2676-2684.
46. Frustaci S, Foladore S, Buonadonna A, De Paoli A, Crivellari D, Carbone A, et al. Epirubicin and ifosfamide in advanced soft tissue sarcomas. Ann Oncol. 1993;4(8):669-672.
47. Palumbo R, Neumaier C, Cosso M, Bertero G, Raffo P, Spadini N, et al. Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study. Eur J Cancer. 1999;35(1):66-72.
48. Reichardt P, Tilgner J, Hohenberger P, Dorken B. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol. 1998;16(4):1438-1443.
49. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185-229.
50. Monk BJ, Herzog T, Kaye S, Krasner CN, Vermorken J, Muggia F, et al. A randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian cancer (OC). Annals of Oncology. 2008;19(Suppl 8):viii1-viii4, LBA4; doi:10.1093/ annonc/mdn1649.